NCT07312799

Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322

A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 in Healthy Adult Volunteers

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 41 (estimated)
• Sponsor: Addpharma Inc. · Industry
• Sex: All
• Age: 19 Years – 64 Years
• Healthy volunteers: Accepted

Summary

To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Treatment A(AD-2321)	AD-2321 Oral Tablet
DRUG	Treatment B(AD-2322)	AD-2322 Oral Tablet
DRUG	Treatment C(AD-2321+AD-2322)	AD-2321 Oral Tablet+AD-2322 Oral Tablet

Timeline

• Start date: 2026-01-27
• Primary completion: 2026-02-11
• Completion: 2026-02-26
• First posted: 2025-12-31
• Last updated: 2025-12-31

Locations

1 site across 1 country: South Korea